A small amount of fat does not affect piperaquine exposure in patients with malaria

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 9, 2011, Pages 3971-3976

  Annerberg, Anna ^a,b   Lwin, Khin Maung ^c   Lindegardh, Niklas ^a,b   Khrutsawadchai, Sakchai ^c   Ashley, Elizabeth ^c   Day, Nicholas P J ^a,b   Singhasivanon, Pratap ^a   Tarning, Joel ^a,b   White, Nicholas J ^a,b   Nosten, François ^a,b,c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c SHOKLO MALARIA RESEARCH UNIT   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROARTEMISININ PLUS PIPERAQUINE; DUO COTECXIN; FAT; MEBENDAZOLE; UNCLASSIFIED DRUG; WATER;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; DIET RESTRICTION; DRUG CLEARANCE; DRUG EXPOSURE; DRUG TOLERABILITY; FAT INTAKE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MILK; PRIORITY JOURNAL; VOLUNTEER;

ADOLESCENT; ADULT; AGED; ARTEMISININS; CHROMATOGRAPHY, LIQUID; DIETARY FATS; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; QUINOLINES; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 80051825842     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00279-11     Document Type: Article

References (33)

1. Ahmed, T., et al. 2008. Safety, tolerability, and single- and multiple-dose pharmacokinetics of piperaquine phosphate in healthy subjects. J. Clin. Pharmacol. 48:166-175.
2. Ashley, E A, et al. 2005. A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin. Infect. Dis. 41:425-432. (Pubitemid 41099632)
3. Ashley, E A, et al. 2007. How much fat is necessary to optimize lumefantrine oral bioavailability? Trop. Med. Int. Health 12:195-200.
4. Brockman, A., et al. 1999. Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand. Am. J. Trop. Med. Hyg. 60:14-21. (Pubitemid 29065997)
5. Chen, L., F Y Qu, and Y C Zhou. 1982. Field observations on the antimalarial piperaquine. Chin. Med. J. 95:281-286. (Pubitemid 12062202)
6. Crevoisier, C., J. Handschin, J. Barre, D. Roumenov, and C. Kleinbloesem. 1997. Food increases the bioavailability of mefloquine. Eur. J. Clin. Pharmacol. 53:135-139. (Pubitemid 27491666)
7. Davis, T M, T Y Hung, I K Sim, H A Karunajeewa, and K F Ilett. 2005. Piperaquine: A resurgent antimalarial drug. Drugs 65:75-87. (Pubitemid 40143802)
8. Denis, M B, et al. 2006. Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop. Med. Int. Health 11:1800-1807. (Pubitemid 44813874)
9. Dien, T K, et al. 1997. Effect of food intake on pharmacokinetics of oral artemisinin in healthy Vietnamese subjects. Antimicrob. Agents Chemother. 41:1069-1072. (Pubitemid 27194187)
10. Ezzet, F., M. Van Vugt, F. Nosten, S. Looareesuwan, and N J White. 2000. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob. Agents Chemother. 44:697-704. (Pubitemid 30117964)
11. Fitoussi, S., et al. 2009. Bioavailability of a co-formulated combination of amodiaquine and artesunate under fed and fasted conditions. A randomised, open-label crossover study. Arzneimittel-Forschung 59:370-376.
12. Hai, T N, S F Hietala, N. Van Huong, and M. Ashton. 2008. The influence of food on the pharmacokinetics of piperaquine in healthy Vietnamese volunteers. Acta Trop. 107:145-149.
13. Humberstone, A J, C J Porter, G A Edwards, and W N Charman. 1998. Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state. J. Pharm. Sci. 87:936-942. (Pubitemid 28381250)
14. Hung, T Y, et al. 2004. Population pharmacokinetics of piperaquine in adults and Children with uncomplicated falciparum or vivax malaria. Br. J. Clin. Pharmacol. 57:253-262.
15. Lindegardh, N., A. Annerberg, N J White, and N P Day. 2008. Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of piperaquine in plasma stable isotope labeled internal standard does not always compensate for matrix effects. J. Chromatogr. 862:227-236.
16. Looareesuwan, S., et al. 1987. Studies of mefloquine bioavailability and kinetics using a stable isotope technique: A comparison of Thai patients with falciparum malaria and healthy Caucasian volunteers. Br. J. Clin. Pharmacol. 24:37-42. (Pubitemid 17087673)
17. Milton, K A, G. Edwards, S A Ward, M L Orme, and A M Breckenridge. 1989. Pharmacokinetics of halofantrine in man: Effects of food and dose size. Br. J. Clin. Pharmacol. 28:71-77. (Pubitemid 19195667)
18. Nguyen, D V, et al. 2009. Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam. Antimicrob. Agents Chemother. 53:3534-3537.
19. Nguyen, T C, et al. 2008. Short report: Pharmacokinetics of the antimalarial drug piperaquine in healthy Vietnamese subjects. Am. J. Trop. Med. Hyg. 79:620-623.
20. Price, R N, et al. 2007. Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Antimicrob. Agents Chemother. 51:4090-4097. (Pubitemid 350057809)
21. Rolan, P E, et al. 1994. Examination of some factors responsible for a food-induced increase in absorption of atovaquone. Br. J. Clin. Pharmacol. 37:13-20. (Pubitemid 24204575)
22. Silamut, K., P. Molunto, M. Ho, T M Davis, and N J White. 1991. Alpha 1-acid glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malaria. Br. J. Clin. Pharmacol. 32:311-315.
23. Silamut, K., N J White, S. Looareesuwan, and D A Warrell. 1985. Binding of quinine to plasma proteins in falciparum malaria. Am. J. Trop. Med. Hyg. 34:681-686. (Pubitemid 16237009)
24. Sim, I K, T M Davis, and K F Ilett. 2005. Effects of a high-fat meal on the relative oral bioavailability of piperaquine. Antimicrob. Agents Chemother. 49:2407-2411.
25. Smithuis, F., et al. 2006. Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: An open-label randomised comparison. Lancet 367:2075-2085. (Pubitemid 43949291)
26. Tarning, J., et al. 2008. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob. Agents Chemother. 52:1052-1061. (Pubitemid 351358388)
27. Tarning, J., et al. 2005. Pitfalls in estimating piperaquine elimination. Antimicrob. Agents Chemother. 49:5127-5128. (Pubitemid 41778931)
28. Tarning, J., et al. 2008. Pharmacokinetics and metabolism of the antimalarial piperaquine after intravenous and oral single doses to the rat. J. Pharm. Sci. 97:3400-3410.
29. Trenholme, G M, R L Williams, K H Rieckmann, H. Frischer, and P E Carson. 1976. Quinine disposition during malaria and during induced fever. Clin. Pharmacol. Ther. 19:459-467.
30. Valecha, N., et al. 2010. An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia. PLoS One 5:e11880.
31. White, N J 1985. Clinical pharmacokinetics of antimalarial drugs. Clin. Pharmacokinet. 10:187-215. (Pubitemid 15093446)
32. White, N J, et al. 1982. Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria. Am. J. Med. 73:564-572. (Pubitemid 12003291)
33. White, N J, M. Van Vugt, and F. Ezzet. 1999. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. Clin. Pharmacokinet. 37:105-125.